Lunai Bioworks Inc. 8-K

What Happened

• On June 11, 2026, Lunai Bioworks, Inc. (LNAI) received a letter from The Nasdaq Stock Market LLC confirming the Nasdaq Hearings Panel determined the company has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the $1.00 minimum bid-price requirement).
• Nasdaq noted Lunai met the terms of the Panel’s decision and extension letters dated April 20, 2026 and May 12, 2026, but informed the company it will be subject to a mandatory Panel monitor for one year under Nasdaq Listing Rule 5815(d)(4)(B).

Key Details

• Date of Nasdaq letter: June 11, 2026.
• Listing Rule regained: Nasdaq Listing Rule 5550(a)(2) — $1.00 minimum bid price.
• Prior Panel communications: decisions/extension letters dated April 20, 2026 and May 12, 2026.
• Monitoring period: one year under Rule 5815(d)(4)(B). If Nasdaq staff finds Lunai out of compliance again for the same bid-price deficiency, the company will not be allowed to submit a compliance plan or receive additional cure time per Rules 5810(c)(2) and 5810(c)(3); Nasdaq staff would issue a delist determination letter.
• Company remedy: Lunai may request a new hearing before the Nasdaq Hearings Panel under Rule 5815(d)(4)(C), and that hearing request would stay any suspension or delisting action pending the hearing’s outcome.

Why It Matters

• Regaining compliance avoids immediate delisting and keeps LNAI shares trading on Nasdaq, which supports liquidity and investor access.
• The one-year mandatory monitor raises the stakes: a repeat drop below the $1.00 bid-price for the same deficiency could trigger a rapid delisting process without the usual cure periods, though the company can seek a hearing to contest the determination.
• Investors should watch Lunai’s share price and company updates closely during the monitoring period because Nasdaq’s increased oversight increases near-term listing risk.